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1. Introduction 
Gamma Knife radiosurgery is a well validated option for the treatment of brain metastases 
existing solid evidence reinforcing his role in the management of these tumors.  
The result achieved with this technique in terms of tumor control and survival is comparable 
to results obtained with surgery plus whole brain irradiation. Radiosurgery has the 
advantages of lower complications; allow treatment of multiple lesions, permits treatment of 
lesions deeply located or in high functional zones, rapid recovery and lower cost.  
Although radiosurgery could be useful for tumor control, increase survival and improved 
quality of life, there are some clinical situations where the treatment can be considered 
applicable and justified and others where radiosurgery could not be recommended. 
For the estimation of survival many variables have been identified, the most important seem 
to be the Karnofsky performance status, control of the cancer disease either at the primary 
site as well as at the systemic level (dissemination) and the number of brain metastases. 
Regarding the different variables studied in the present chapter, each variable was arranged 
in 1 of 5 powered categories according to the number of publications and the agreement of 
their findings. 
1. Consistent agreement: there are clear coincidental conclusions among the publications, 
without controversial findings. In this category is highly possible that the conclusion is 
right. 
2. Reasonable agreement: there are more coincidental conclusions among the 
publications, but with some controversial findings. In this category is quite possible that 
the conclusion is right. 
3. Some agreement with a trend: there are less coincidental conclusions among the 
publications, more controversial findings but a trend is observed. In this category the 
conclusion could be right but more information is recommended. 
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4. Scarce information with a trend: A trend is observed, but because the small quantity of 
data more information is recommended for definitive conclusions. 
5. Scarce information with no clear trend or controversial findings: In these cases more 
information is absolutely needed for having any conclusion. 
Two plots for each variable were built. The first plot represents the number of publications 
(papers) supporting the prognostic value of the variable and the second plot shows the 
number of patients enrolled in such studies: better (variable is a positive prognostic factor), 
unaffected (variable is not a prognostic factor) and worse (variable is a negative prognostic 
factor).  
Integrating these variables many stratification systems have been proposed for survival 
estimation: “Recursive Partitioning Analysis”, “Score Index for Radiosurgery in Brain 
Metastases”, Basic Score for Brain Metastases” and “Graded Prognostic Assessment Index”. 
All of these stratifications systems allow estimating survival for a particular patient. In this 
chapter some more details will be given concerning the most used systems. 
2. Prognostic factors for survival 
2.1 Karnofsky performance status (KPS) 
This variable represents the most powerful prognostic factor for survival. The majority of 
studies show significant influence of KPS  in multivariate analysis (Simonová, 2000); Sneed, 
2002; Petrovich, 2002; Wowra, 2002; Schoeggl, 2002; Hasegawa, 2003; Muacevic, 2004; 
Serizawa, 2005; Pan, 2006; Gaudy, 2006; Rades, 2007; Matuiew, 2007; Golden, 2008; Kased, 
2009; Da Silva, 2009; Aba cioglu, 2010; Kondziolka 2011; Matsunaga 2011; Liew, 2011). 
Others authors have communicated significance in univariate studies (Chidel, 2000; 
Amendola, 2002; Lorenzoni, 2004; Frazier, 2010; Skeie, 2011). A few studies found no 
influence of KPS in survival (Vesagas, 2002; Hernandez, 2002; Flannery, 2003; Gerosa, 2005), 
nevertheless, three of these four studies have a small number of patients. A favorable 
Karnofsky performance status (≥70 or 80) influences positively the survival with “consistent 
agreement”. 
  
2.2 Systemic cancer control status 
This variable is used for many authors as an evaluation tool for the systemic extracranial 
integrated situation of the cancer progression, taking into account at once the control of 
the primary tumor site as well as the existence of extracranial metastases. Others authors 
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prefer to study separately the primary tumor control and the extracranial dissemination. 
Considering the systemic “extracranial” cancer status, there is also predominance of 
multivariate analysis proving its positive influence on survival (Petrovich, 2002; Serizawa, 
2005; Mathiew, 2007; Kondziolka, 2011; Liew, 2011). In univariate studies 3 
communications show this influence too (Hasegawa, 2003; Yu, 2005; Karlsson , 2009). Just 
one publication (Hernández 2002) found no influence of this variable on survival; this is a 
publication reporting 29 patients with renal cell carcinoma. The present study found a 
positive influence of Systemic cancer control status on survival with “consistent 
agreement”.   
  
2.3 Extracranial metastases 
The existence of extracranial metastatic disease has been identified as a negative prognostic 
factor for survival by the majority of authors either in multivariate studies (Simonová, 2000; 
Sneed, 2002; Rades, 2007; Golden, 2008; Matsunaga, 2011; Skeie, 2011) and in univariate 
studies (Chidel, 2000; Wowra, 2002; Lorenzoni, 2004; Yu, 2005; Pan, 2005). Some others 
manuscripts have shown no influence of this variable on survival (Hernández, 2002; 
Schoeggl, 2002; Jawahar, 2004; Gaudy, 2006; Kased, 2009; Da Silva, 2009; Kondziolka, 2011). 
Concerning the existence of extracranial metastases a negative influence on survival was 
found with “reasonable agreement”. 
  
2.4 Control of the primary tumor 
Positive influence of controlled primary site has been reported in multivariate study (Sneed, 
2002) and in univariate studies (Lorenzoni, 2004; Jawahar, 2004; Pan, 2005; Kased, 2009). 
Some studies did not find significant influence (Chidel, 2000; Hernández, 2002; Golden, 
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2008). A positive effect on survival of the control of the primary tumor was observed with 
“reasonable agreement”. 
  
2.5 Bigger size of brain metastases 
Gamma Knife radiosurgery in general indicated to patients with brain metastases with a 
diameter up to 3 centimeters or a volume up to 13 cubic centimeters. Some authors consider 
the diameter of the lesions; others consider volume and others take into account the addition 
of the volume of all lesions when multiple metastases are treated. An unfavorable influence 
of larger size of lesions have been reported  in multivariate studies (Petrovich, 2002; Gaudy, 
2006; Abacioglu, 2010, Kondziolka, 2011; Skeie, 2011) and in univariate studies (Simonová, 
2000; Nam, 2005; Feigl, 2006; Karlsson, 2009; Kased, 2009; Frazier, 2010; Liew, 2011). No 
influence was communicated too (Hernández, 2002; Hasegawa, 2003; Lorenzoni, 2004; 
Serizawa, 2005; Yu, 2005; Gerosa, 2005; Da Silva, 2009). With regard the size of metastases a 
bigger size or total tumoral volume was associated with a poor survival with “reasonable 
agreement”. 
  
2.6 Multiple LGK treatments 
After a Gamma Knife treatment for brain metastases, along the time new metastases can 
develop, in such situations a new Gamma Knife treatment can be offered to these patients, 
Pan (Pan, 2005) found a positive influence on survival the realization of a new treatments in 
multivariate analysis. Vesagas (Vesagas, 2002) and Yu (Yu, 2005) found benefice in 
univariate studies. Conversely, two authors (Hernández, 2002; Wowra, 2002) did not find 
any effect. Concerning new Gamma Knife treatments, a positive effect on survival has been 
observed with “scarce information with a trend”. 
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2.7 Number of brain metastases 
The study of this variable is nowadays a challenge and not definitive conclusions have been 
stated concerning the maximal number of lesions that is reasonable to treat. A negative 
influence on survival of larger number of metastases have been found in multivariate 
analysis (Sneed, 2002; Gudy, 2006; Mathiew, 2007; Golden, 2008; Abacioglu, 2010; Liew, 
2011) and in univariate ones (Vesagas, 2002; Wowra, 2002; Radbill, 2004; Nam, 2005; 
Serizawa, 2005; Gerosa, 2005; Feigl, 2006; Karlsson, 2009; Kondziolka, 2011; Matsunaga, 
2011). Others investigators on the other hand have informed no influence of this factor on 
survival (Chidel, 2000; Petrivich, 2002; Hernández, 2002; Schoeggl, 2002; Hasegawa, 2003; 
Lorenzoni, 2004; Jawahar, 2004; Muacevic, 2004; Yu, 2005; Rades, 2007; Kased, 2009; Frazier, 
2010; Skeie, 2011). When on observe the number of patients reported in the papers, it is 
possible to recognize that in average those manuscripts showing no influence of this 
variable on survival have less number of patients (put in evidence in the plot dealing with 
the number of patients).  It seems that a higher number of brain metastases affect negatively 
the survival with “reasonable agreement”.   
With regard the number of brain metastases that is reasonable to treat, the higher level of 
evidence recommends to treat up four lesions, based in three prospective, randomized 
studies (Metha, 2005), nevertheless, these 3 studies included patients with a maximum of 3 
or 4 lesions, then, patients with higher number of metastases were not studied. 
Nam (Nam, 2005) compared a group of 84 patients with up to three brain metastases with 46 
harboring 4 or more lesions. The survival of the second group (26 weeks) was significantly 
less than 48 weeks in the group with up to 3 metastases, Nevertheless when a multivariate 
analysis was done, only the RPA stratification system was the independent factor affecting 
survival. The author concluded that the Karnofsky performance status and the RPA 
stratification should be considered as the most important factors and multiplicity of the 
lesions alone should not be a reason for withholding Gamma Knife treatment.  
Karlsson (Karlsson, 2009) in a multicentric retrospective study involving 1855 patients found 
no difference on survival among patients with single or multiple metastases when the the 
systemic status of the cancer was controlled. Moreover, there was no difference in overall 
survival comparing patients harboring 2 metastases, 3 to4 metastases, 5-8 metastases or ≥9 
metastases. 
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Chang (Chang, 2010), in a series of 323 patients studied the influence on survival of the 
number of brain metastases. The survivals were not significantly different between patient 
with 1 to 5 lesions (10 months), 6 to 10 lesions (10 months), 11 to 15 lesions (13 months) and 
≥15 lesions (8 months). The author concluded that Gamma Knife radiosurgery may be a 
good treatment option for local control of metastatic lesions and for improved survival in 
patients with multiple metastatic brain lesions, even those patients who harbor more than 15 
brain metastases. 
Serizawa (Serizawa, 2010) studied 778 patients with the following 6 inclusion criteria: 
newly diagnosed brain metastases, one to 10 lesions, up to 10cc of maximal volume of the 
larger metastasis, less than 15cc of total intracranial tumoral volume, No evidence on 
magnetic resonance of meningeal tumor dissemination and a KPS ≥70. There was no 
upfront use of whole brain irradiation. The overall survival was 8.6 months (0.72 years). 
There were not differences in survival between patients with single, two, 3 to 4, 5 to 6 and 
7 to 10 brain metastases. The study conclusion was that the brain lesion number has no 
effect on survival. 
Some concerns could exist in relation to the total integral dose received by the normal brain 
when numerous lesions are treated; Yamamoto (Yamamoto, 2002) studied the safety of this 
treatment situation in 80 patients with 10 or more brain lesion that underwent Gamma Knife 
treatment. The conclusion was that the cumulative whole brain irradiation was not 
exceeding the threshold level of normal brain necrosis. 
With regard the number of brain metastases it seems that selecting patients with favorable 
Karnofsky performance status and having a controlled cancer, up to 10 or even up to 15 
brain metastases could be reasonable treated, nevertheless, prospective randomized trials 
are desirable.  
    
2.8 Older age 
Most manuscripts show no influence of this factor on survival (Simonová, 2000; Petrovich, 
2002; Hernández, 2002; Wowra, 2002; Schoeggl, 2002; Lorenzoni, 2004; Jawahar, 2004; Nam, 
2005; Serizawa, 2005; Yu, 2005; Gerosa, 2005; Da Silva, 2009; Kondziolka, 2011; Matsunaga, 
2011), nevertheless, when the number of patients enrolled in such studies is observed, 
bigger studies report a negative influence of an older age on survival in multivariate studies 
(Hasegawa, 2003; Pan, 2006; Gaudy, 2006; Rades, 2007; Golden 2008) as well as univariate 
ones (Sneed, 2002; Muacevic, 2004; Karlsson, 2009; Kased, 2009; Frazier, 2010; Liew, 2011). 
Older age influences negatively the survival with “some agreement with a trend”. 
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2.9 Female gender 
Most studies have shown that gender is not a prognostic factor for survival (Wowra, 2002; 
Schoeggl, 2002; Hasegawa, 2003; Flannery, 2003; Lorenzoni, 2004; Jawahar, 2004; Nam, 2005; 
Rades, 2007; Mathiew, 2007; Frazier, 2010; Matsunaga, 2011), a few reports have shown 
positive influence of female gender on survival in multivariate analysis (Serizawa, 2005) and 
in univariate analysis (Amendola, 2002; Gaudy, 2006; Liew, 2011). It appears that gender do 
not affect survival with “Some agreement with a trend”. 
  
2.10 Location or histology of the primary tumor 
No influence on survival of the primary tumor have been reported (Lorenzoni, 2004; Nam, 
2005; Rades, 2007; Frazier, 2010), on the other hand other studies have demonstrated significant 
association of this variable with survival: Hasegawa (Hasegawa, 2003), in the multivariate 
analysis found significant lower survival in patients harboring malignant melanoma. In 
multivariate studies Simonová (Simonová, 2000) reported better survival in patients with 
breast or renal cancer, Petrovich (Petrovich, 2002) found worse survival in patients with 
Melanoma and colon cancer and better survival in patients with breast cancer. Vesagas 
(Vesagas, 2002) communicated better survival in patients with breast carcinoma. “Scarce 
information with a trend” could suggest that primary melanoma or colon cancer could be a 
negative prognosric factors for survival, and breast could be a positive prognostic factor.  
2.11 Location of the brain metastases 
Kondziolka (Kondziolka, 2011) in a series of 350 patients with breast cancer found a 
negative influence on survival of the brainstem location in multivariate analysis and a deep 
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brain location of lesions in the univariate study. Gaudy-Marqueste (Gaudy-Marqueste, 2006) 
found worse survival in a multivariate study in patients harboring deep location of the 
lesions in a series of 106 patients with melanoma brain metastases. Others authors 
(Mathiew, 2007, Liew, 2011) have found in multivariate analysis that cerebellar tumor 
location was associated to poorer survival. Regarding tumor location, “scarce information 
with a trend” suggests that brainstem location, deep brain location and cerebellar location 
of a melanoma metastasis could be negative prognostic factors. 
2.12 Latency period to brain metastases diagnose 
The time elapsed between the diagnosis of the cancer and the moment of the apparition of 
brain metastases has been propose as a prognostic factor, two studies have shown this 
association on multivariate analysis (Flanery, 2003; Rades, 2007) and 3 studied on univariate 
analysis (Yu, 2005; Kased, 2009; Liew, 2011). Seven investigators did not found this influence 
(Wowra, 2002; Schoeggl, 2002; Muacevic, 2004; Serizawa, 2005; mathiew, 2007; Kondziolka, 
2011; Matsunaga, 2011). “some agreement with a trend” could suggest that a longer latency 
period could be associated with longer survival. 
  
2.13 HER2/neu receptors (breast) 
The two publications revised (Kassed, 2009; Kondziolka, 2011) have shown on multivariate 
analysis a positive association of the existence of the HER2/neu receptors with a favorable 
survival. In spite of the strong association, it was considered that “scarce information with a 
trend” support this finding. 
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2.14 Estrogen receptors (breast) 
Among two publications revised, one found positive influence of the existence of estrogen 
receptors on survival (Kassed, 2009). Kondziolka (Kondziolka, 2011) on the other hand, 
report no influence of this variable on survival. “Scarce information with a trend” could 
suggest that the presence of estrogen receptors could be associates with a longer survival. 
  
2.15 Whole brain radiotherapy 
This was the only prognostic factor in the present study where after the analysis of many 
manuscripts absolute “consistent agreement” exists. All the articles revised report no benefit 
in terms of survival when whole brain radiotherapy is added to Gamma Knife radiosurgery 
(Chidel, 2000; Sneed, 2002; Petrovich, 2002; Jawahar, 2002; Vesagas, 2002; Schoeggl, 2002; 
Flannery, 2003; Lorenzoni, 2004; Muacevic, 2004; Nam, 2005; Gerosa, 2005; Pan, 2005; 
Mathiew, 2007; Da Silva, 2009; Frazier, 2010, Abacioglu, 2010; Liew, 2011; Skeie, 2011).   
  
3. Stratification systems used in radiosurgery 
The combination and integration of some of the strongest prognostic factors allow creating 
score systems or stratification systems as tools for patient survival estimation. Many of these 
have been proposed and all of them have shown to be reliable:  
3.1 Recursive Partitioning Analysis (RPA) 
This system is the most used and widely known. It was proposed initially for patients treated 
with whole brain radiotherapy (Gaspar, 1997; Gaspar, 2000) and subsequently tested and used 
for radiosurgery (Sanghavi, 2001; Lorenzoni, 2004; Nieder, 2009). It considers Karnofsky, age, 
the control of the primary tumor and the existence of extracranial metastases (table 1). 
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In the study of Sanghavi (Sanghavi, 2001) the median survival for patients in cathegories I, II 
and III were 16.1, 10.3 and 8.7 months respectively. Subsequently, in the study of Lorenzoni 
(Lorenzoni 2004) the survival were 27.6, 10.7 and 2.8 months for classes I, II and III 
respectively. This score system has not good specificity for detecting patients with short 
survival. In the study of Lorenzoni (Lorenzoni, 2004) the maximal survival reached by 
patients in the poorer category (RPA III) was 11 months. The advantage of RPA is to be a 
reliable and easy system. As a disadvantage it could be considered the heterogeneity of the 
category II and as it was mentioned before it´s relative reduced capacity for detecting 
patients with very short survival. 
 
RPA I: 
  
  
  
RPA II: 
  
RPA III:  
Karnofsky ≥ 70 
Age less than 65 years 
Primary tumor controlled 
No extracranial metastases  
Karnofsky ≥ 70 
Do not fulfill criteria for RPA I 
Karnofsky < 70 
Table 1. RPA. 
3.2 Score Index for Rradiosurgery in brain metastases (SIR) 
The “Score index for radiosurgery in brain metastases” (SIR) was described by Weltman 
(Weltman, 2000; Weltman, 2001) and validated afterwards (Lorenzoni, 2004). It uses five 
prognostic factors: Age, Karnofsky, systemic disease status, the size and the number of 
lesions (table 2). 
In the article of Weltman (Weltman, 2000), the survivals for patients with scores 8-10, 4-7 
and 1-3 were 31.4, 7 and 2.9 months respectively. In the study of Lorenzoni (Lorenzoni, 
2004), the survivals were 27.7, 10.8, 4.6 and 2.4 for patients with scores 8-10, 5-7, 4 and 1-3 
respectively. In the study of Lorenzoni SIR was the best system according to statistic 
significance. This score system represents quite a good specificity for detecting patients with 
short survival; in the study of Lorenzoni (Lorenzoni, 2004) the maximal survival reached by 
patients in the poorer category was 7 months. SIR has a more complex format what could be 
considered a relative disadvantage. 
 
Variable  
Age  
Karnofsky  
Systemic disease status  
Large lesión volume (cc)  
Number of lesions  
0 
≥60 
≥50 
PD 
>13 
≥3 
1 
51-59 
60-70 
PR-SD 
5-13 
2 
2 
≤50 
≥80 
CR-NED 
<5 
1 
(Range: 0 to 10 points) 
PD: progressive disease, PR: partial remission, SD: stable disease, CR: complete remission, NED: no 
evidence of disease. 
Table 2. SIR. 
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3.3 Basic Score for Brain Metastases (BSBM) 
The Basic score for brain metastases was described by Lorenzoni (Lorenzoni, 2004; 
Lorenzoni, 2009). It was conceived as an attempt to develop a score system with a good 
balance between reliability and simplicity. It takes into account the three most powerful 
prognostic factors for survival (karnofsky, Control of the primary tumor and the existence of 
extracranial metastases), assigning on point for each factor (Table 3). Additionally, when 
associations of variables were analyzed in the original study (Lorenzoni, 2004), an 
“intrinsic” representation of other two linked variables (number of lesions and size of 
lesions) was demonstrated:  1- The number of lesions is represented by the existence of 
extracranial metastases (60% of patients with 3 or more brain metastases had extracranial 
metastases versus just 36% of patients with one or two brain metastases, p=0.04) and 2- The 
maximal size of lesions is represented by the Karnofsky (50% of patients with a brain 
metastasis volume ≥ 9 cc had an unfavorable Karnofsky index versus just 16% of patients 
with a maximal volume less than 9cc, p=0.01). This system does not take into account the 
patient age.  
In the original manuscript of Lorenzoni (Lorenzoni, 2004), the survival was undefined (more 
than 50% of patients alive at 32 months) in patients with scores 3, 13.1 months for score 2, 3.3 
months for score 1 and 1.9 months for score 0. This score system presented the best 
specificity for detecting patients with short survival: the maximal survival reached by any 
patient in the poorer category (score 0) was only 4 months. The main advantages of BSBM is 
it extreme simplicity and as it was mentioned, the high capacity for detecting patients with a 
very poor life expectancy. 
 
Karnofsky ≥ 80                              
Primary tumor controlled           
No extracranial metastases        
1 point 
1 point 
1 point 
 (Range: 0 to 3 points)
Table 3. BSBM. 
3.4 Others score systems for radiosurgery 
Some other authors have proposed systems such as GGS (Golden, 2008), and a Melanoma-
specific system, MM.GKR (Gaudy-Marqueste, 2006). 
4. Stratification systems tested with whole brain radiotherapy databases 
Some systems have been developed recently based on databases of patients treated with 
fractionated whole brain irradiation but not jet tested for stereotactic radiosurgery. The 
graded prognostic assessment index (GPA) and some primary tumor-specific scores are 
the most common. All of these systems could be useful for patients treated with 
radiosurgery but its efficiency must be proved. Some differences could be found with 
regard to statistical testing, in fact, the survival of patients treated with radiosurgery 
could be twice compared with the survival of patients treated with whole brain 
radiotherapy (Sanghavi, 2001). 
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4.1 Graded Prognostic Assessment Index (GPA) 
Proposed by Sperduto (Sperduto, 2008) using the RTOG database of 1960 patients treated 
with whole brain radiotherapy from five randomized prospective trials. It considers four 
prognostic factors: Age, Karnofsky, number of lesions and the existence of extracranial 
metastases (figure 4). GPA has also a more complex format that could be considered a 
relative disadvantage. 
In the original article of Sperduto (Sperduto, 2008), in addition to the description of the 
GPA, the author performed a study using also others pre-existing score systems (RPA, SIR 
and BSBM). According to RPA, the survivals reported were 7.7, 4.5 and 2.3 months for 
patients in the categories I, II and III respectively. 
Using SIR, the survivals were 8.8, 6 and 2.1 months for the scores 8-10, 4-7 and 1-3 
respectively. With regard BSBM, the survivals were 7, 5.1, 3.4 and 2.2 months for scores 3, 2, 
1, and 0 respectively. 
In the GPA proposed the survivals were 11, 6.9, 3.8 and 2.6 months for patients with scores 
3.5-4, 3, 1.5-2.5 and 0-1.  
Nieder (Nieder, 2008) tested this score in 232 patients treated with whole brain 
radiotherapy. According to RPA, the survivals reported were 10.8, 3.2 and 2 months for 
patients in the categories I, II and III respectively. Using SIR, the survivals were 8.7, 4.1 
and 1.7 months for the scores 8-10, 4-7 and 1-3 respectively. With regard BSBM, the 
survivals were 11.5, 3.9, 2.4 and 1.9 months for scores 3, 2, 1, and 0 respectively. In the 
GPA proposed the survivals were 10.3, 5.6, 3.5 and 1.9 months for patients with scores 3.5-
4, 3, 1.5-2.5 and 0-1.  
Concerning the capacity for detecting patients with the poorer survival, the most efficient 
system was the “basic score for brain metastases” (BSBM) (Nieder, 2010; Villà, 2011). 
 
Variable                  
Age                                        
Karnofsky                            
Number of lesions             
Extracranial metastases   
0     
≥60     
<70     
>3     
yes    
0.5  
51-59    
70-80    
2-3        
-           
1  
≤50 
90-100 
1 
No  
(Range: 0 to 4 points) 
Table 4. GPA. 
4.2 Others primary tumor-specific score systems tested for whole brain radiotherapy 
Other authors have proposed primary-specific systems, such as Breast cancer-specific score 
(Nieder, 2009), Breast-GPA (Sperduto, 2011), and Melanoma-GPA (Sperduto, 2010) among 
others.  
5. Conclusions 
Gamma Knife radiosurgery is a highly effective method for controlling brain metastases and 
it can be useful and safely offered to those patients that fulfill the following conditions:   
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1. Karnofsky performance status ≥ 70,  
2. Tumors with a maximum diameter of 3 centimeters or a maximum volume of 13 cubic 
centimeters. 
3. No significant mass effect and absence of intracranial hypertension. 
4. No evidence of leptomeningeal dissemination. 
5. Up to 10 to 15 brain lesions (more recent observational non randomized studies) or up 
to 4 brain lesions (prospective randomized trials). 
6. Up to 15 cubic centimeters of total tumor mass. 
7. Systemic cancer diseases well controlled (desirable but not excluding condition). 
Many prognostic factors for survival have been identified, among them, Karnofsky 
performance status (KPS) have been considered the most powerful followed by the status of 
the cancer disease (overall systemic cancer status or a separate analysis of the control of the 
primary site and the existence of extracranial metastases).  
The integration of many prognostic factors has originated score systems for survival 
estimation, all of these scores are reliable, and the election of one of them should be 
according with the best compromise with reliability and simplicity. Some scores must be 
proved for radiosurgery and probably in the future new or improved specific scores will be 
available and tested for stereotactic radiosurgery. 
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